Gina Chung, MD
Medical Oncology · Cincinnati, OHNPI 1861480543
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,273 of the $12,861 with a category attached, or 72.1%. AstraZeneca accounts for 81.6% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2019 at $5,750 and has fallen 96.7% since, to $187 in 2025.
Across 141 payments — averaging $91.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Johnson & Johnson$213
- Novartis$211
- Merck$200
- Genentech USA, Inc.$157
- Astellas Pharma US Inc$137
- plus $1K from 36 others
Across 31 payments — averaging $20,114 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$293K
- AstraZeneca$278K
- Veru Inc.$22K
- Astrazeneca UK Limited$16K
- Amgen$7K
- Pfizer$7K
- plus $1K from 1 others
What the payments were for
- Consulting fees$9,27372%
- Travel & lodging$8246%
- Food & beverage$2,42319%
- Education$3423%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $10,489 |
| Johnson & Johnson(2 entities) | 12 | $213 |
| Novartis | 12 | $211 |
| Merck | 12 | $200 |
| Genentech USA, Inc. | 6 | $157 |
| Astellas Pharma US Inc | 3 | $137 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $122 |
| Amgen | 6 | $113 |
| Taiho Oncology, Inc. | 1 | $105 |
| E.r. Squibb & Sons, L.L.C. | 6 | $100 |
| Eisai Inc. | 4 | $75 |
| Pfizer | 5 | $63 |
| Daiichi Sankyo Inc. | 4 | $60 |
| Sanofi | 3 | $59 |
| Bayer | 3 | $57 |
| Puma Biotechnology, Inc. | 3 | $48 |
| Exelixis Inc. | 1 | $46 |
| Tempus AI, Inc | 2 | $44 |
| Foundation Medicine, Inc. | 1 | $39 |
| GSK | 2 | $36 |
| Tesaro, Inc. | 2 | $34 |
| AbbVie | 2 | $32 |
| Lilly USA, LLC | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $31 |
| Dova Pharmaceuticals | 2 | $31 |
| Rigel Pharmaceuticals, Inc. | 2 | $31 |
| Clovis Oncology, Inc. | 2 | $30 |
| Spectrum Pharmaceuticals Inc. | 1 | $30 |
| Tersera Therapeutics LLC | 2 | $29 |
| Boehringer Ingelheim | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Deciphera Pharmaceuticals Inc. | 1 | $17 |
| Seagen Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| EMD Serono, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,861 in reported general payments places this provider in the 75th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 29 | $454,788 |
| IbrancePalbociclib | 15 | $230,358 |
| RevlimidLenalidomide | 11 | $219,905 |
| CalquenceAcalabrutinib Maleate | 11 | $167,888 |
| EliquisApixaban | 90 | $62,470 |
| XareltoRivaroxaban | 22 | $26,512 |
| Exemestane | 61 | $9,951 |
| Potassium Chloride | 26 | $6,077 |
| Letrozole | 388 | $5,842 |
| Tamoxifen Citrate | 107 | $2,090 |
| Enoxaparin Sodium | 11 | $1,840 |
| Anastrozole | 110 | $1,578 |
| Pregabalin | 11 | $1,242 |
| Hydroxyurea | 42 | $723 |
| Oxycodone Hcl | 46 | $616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $122 | $454,78829 claims |
| PfizerIbrance, Eliquis | $63 | $292,828105 claims |
| Bristol Myers SquibbRevlimid | $16 | $219,90511 claims |
| AstraZenecaCalquence | $10,489 | $167,88811 claims |
| Johnson & JohnsonXarelto | $213 | $26,51222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 157 medical oncology providers in Ohio.
Other medical oncology in Cincinnati
- Elyse LowerCincinnati$312K
- John MorrisCincinnati$16K
- Leslie OleksowiczCincinnati$14K
- David CarboneColumbus$438K
- Moshe OrnsteinCleveland$249K
- Christian RolfoColumbus$227K
- Timothy MooreColumbus$213K
- Maryam LustbergColumbus$176K
- Suneel KamathCleveland$120K
- Mark MarinellaKettering$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.